TY - JOUR
T1 - Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity
AU - O'Byrne, Paul
AU - Horner, Caroline C.
AU - Mauger, David
AU - Strunk, Robert C.
AU - Graber, Nora J.
AU - Lemanske, Robert F.
AU - Sorkness, Christine A.
AU - Szefler, Stanley J.
AU - Zeiger, Robert S.
AU - Taussig, Lynn M.
AU - Bacharier, Leonard B.
N1 - 5U10HL064287, NHLBI NIH HHS, United States5U10HL064288, NHLBI NIH HHS, United States5U10HL064295, NHLBI NIH HHS, United States5U10HL064305, NHLBI NIH HHS, United States5U10HL064307, NHLBI NIH HHS, United States5U10HL064313, NHLBI NIH HHS, United StatesM01 RR00036, NCRR NIH HHS, United StatesM01 RR00051, NCRR NIH HHS, United StatesU10 HL064287-10, NHLBI NIH HHS, United StatesU10 HL064288-10, NHLBI NIH HHS, United StatesU10 HL064295-10, NHLBI NIH HHS, United StatesU10 HL064305-10, NHLBI NIH HHS, United StatesU10 HL064307-10, NHLBI NIH HHS, United StatesU10 HL064313-07, NHLBI NIH HHS, United StatesUL1 RR024992, NCRR NIH HHS, United StatesUL1 RR024992, NCRR NIH HHS, United States
PY - 2011/11
Y1 - 2011/11
N2 - Background: Although nocturnal awakenings help categorize asthma severity and control, their clinical significance has not been thoroughly studied. Objective: We sought to determine the clinical consequences of nocturnal asthma symptoms requiring albuterol (NASRAs) in children with mild-to-moderate persistent asthma outside of periods when oral corticosteroids were used for worsening asthma symptoms. Methods: Two hundred eighty-five children aged 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive one of 3 controller regimens and completed daily symptom diaries for 48 weeks. Diary responses were analyzed for the frequency and consequences of NASRAs. Results: NASRAs occurred in 72.2% of participants at least once, and in 24.3% of participants, they occurred 13 or more times. The majority (81.3%) of nocturnal symptoms occurred outside of exacerbation periods and were associated the next day with the following events: albuterol use (56.9% of days preceded by nocturnal symptoms vs 18.1% of days not preceded by nocturnal symptoms; relative risk [RR], 2.3; 95% CI, 2.2-2.4), school absence (5.0% vs 0.3%; RR, 10.6; 95% CI, 7.8-14.4), and doctor contact (3.7% vs 0.2%; RR, 8.8; 95% CI, 6.1-12.5). Similar findings were noted during exacerbation periods (RRs of 1.7 for albuterol use, 5.5 for school absence, and 4.9 for doctor contacts). Nocturnal symptoms did not predict the onset of exacerbations. Conclusion: Nocturnal symptoms requiring albuterol in children with mild-to-moderate persistent asthma receiving controller therapy occurred predominantly outside of exacerbation periods. Despite being poor predictors of exacerbations, they were associated with increases in albuterol use, school absences, and doctor contacts the day after nocturnal symptom occurrences. © 2011 American Academy of Allergy, Asthma & Immunology.
AB - Background: Although nocturnal awakenings help categorize asthma severity and control, their clinical significance has not been thoroughly studied. Objective: We sought to determine the clinical consequences of nocturnal asthma symptoms requiring albuterol (NASRAs) in children with mild-to-moderate persistent asthma outside of periods when oral corticosteroids were used for worsening asthma symptoms. Methods: Two hundred eighty-five children aged 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive one of 3 controller regimens and completed daily symptom diaries for 48 weeks. Diary responses were analyzed for the frequency and consequences of NASRAs. Results: NASRAs occurred in 72.2% of participants at least once, and in 24.3% of participants, they occurred 13 or more times. The majority (81.3%) of nocturnal symptoms occurred outside of exacerbation periods and were associated the next day with the following events: albuterol use (56.9% of days preceded by nocturnal symptoms vs 18.1% of days not preceded by nocturnal symptoms; relative risk [RR], 2.3; 95% CI, 2.2-2.4), school absence (5.0% vs 0.3%; RR, 10.6; 95% CI, 7.8-14.4), and doctor contact (3.7% vs 0.2%; RR, 8.8; 95% CI, 6.1-12.5). Similar findings were noted during exacerbation periods (RRs of 1.7 for albuterol use, 5.5 for school absence, and 4.9 for doctor contacts). Nocturnal symptoms did not predict the onset of exacerbations. Conclusion: Nocturnal symptoms requiring albuterol in children with mild-to-moderate persistent asthma receiving controller therapy occurred predominantly outside of exacerbation periods. Despite being poor predictors of exacerbations, they were associated with increases in albuterol use, school absences, and doctor contacts the day after nocturnal symptom occurrences. © 2011 American Academy of Allergy, Asthma & Immunology.
KW - Asthma
KW - exacerbation
KW - nocturnal symptoms
U2 - 10.1016/j.jaci.2011.07.018
DO - 10.1016/j.jaci.2011.07.018
M3 - Article
C2 - 21855126
SN - 0091-6749
VL - 128
SP - 977-e2
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -